New diabetes drug shows promise in early human tests

NCT ID NCT06685185

First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 27 times

Summary

This early study tested a new medicine called NNC0363-1063 in 117 people, including healthy volunteers and those with type 1 diabetes. The goal was to check safety, how the body processes the drug, and its effects on blood sugar. It is a first step to see if this drug could become a future treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Profil Institut für Stoffwechselforschung GmbH

    Neuss, 41460, Germany

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NNC0363-1063

What this could lead to

If successful, this could point toward a new treatment option for type 1 diabetes that helps manage blood sugar levels.

What could go wrong

This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work as hoped or could have side effects.

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.